

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **INSIDE INFORMATION**

#### **UPDATE ANNOUNCEMENT IN RESPECT OF THE POSSIBLE SUBSCRIPTION PURSUANT TO POSSIBLE APPLICATION FOR WHITEWASH WAIVER**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance and a possible application for whitewash waiver under The Hong Kong Code on Takeovers and Mergers (the “**Takeovers Code**”).

Reference is made to (i) the announcement of the Company dated 8 April 2022 in relation to, *inter alia*, the Memorandum of Understanding regarding the Possible Subscription, which shall be terminated if a definitive Subscription Agreement is not entered into by the Potential Investor and the Company by 30 June 2022 (or such later date as may be agreed between the Potential Investor and the Company) (the “**Long Stop Date**”); and (ii) the monthly progress update announcements of the Company dated 6 May 2022 and 6 June 2022 (collectively, the “**Announcements**”). Unless context otherwise requires, capitalized terms in this announcement shall have the same meaning as defined in the Announcements.

The Company wishes to update its Shareholders and potential investors that the negotiation regarding the Possible Subscription is still in progress. Due to the impact of the COVID-19 pandemic, the progress of the Possible Subscription has been delayed. As the relevant due diligence, audit and valuation work has not been completed, the Company and the Potential Investor will further negotiate the terms of the Possible Subscription. On 28 June 2022 (after trading hours), the Company and the Potential Investor entered into a supplemental memorandum of understanding (the “**Supplemental**

**Memorandum of Understanding**”) which extends the Long Stop Date to 31 December 2022. Save as the aforesaid, other terms of the Memorandum of Understanding shall remain unchanged and continue to be in full force and effect to the extent that those terms were expressed to be legally binding in the first place.

As at the date of this announcement, other than the Memorandum of Understanding with certain legally binding provisions as announced on 8 April 2022 and the Supplemental Memorandum of Understanding, no formal or legally binding agreement in respect of the Possible Subscription has been entered into between the Potential Investor and the Company.

Monthly announcement(s) setting out the progress of the Possible Subscription will continue to be made until an announcement of a firm intention to proceed with the Possible Subscription under Rule 3.5 of the Takeovers Code and the application of the Whitewash Waiver or of a decision is made not to proceed with the Possible Subscription and the application of the Whitewash Waiver. Further announcement(s) will be made by the Company as and when appropriate or required in accordance with the Listing Rules and the Takeovers Code (as the case may be).

**Shareholders and potential investors of the Company should be aware that there is no assurance that the Possible Subscription will materialise or eventually be consummated. The terms of the Possible Subscription are subject to further negotiations between the Company and the Potential Investor, and the completion of the Possible Subscription is subject to the Subscription Agreement being entered into and the satisfaction (or, as the case may be, waiver) of such conditions precedent to completion (including but not limited to approval of the relevant regulatory authorities of the Potential Investor) as may be specified therein. The Possible Subscription may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares and if they are in any doubt about their position, they should consult their professional adviser(s).**

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Hartono James**  
*Chairman, CEO and Executive Director*

28 June 2022

*As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Liang Junxiong; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*